司美格鲁肽专利闸门今日落下，百亿减肥药大战开打：国产司美格鲁肽集体冲线

Core Viewpoint - The expiration of the core patent for Semaglutide on March 20 marks the beginning of a new phase for the GLP-1 industry in China, shifting the focus from legal barriers to market competition and commercialization strategies [2][3]. Group 1: Market Dynamics - The expiration of the patent does not guarantee the immediate availability of generic drugs; the actual competition will depend on regulatory approval, production capabilities, commercialization speed, and pricing strategies [3]. - Currently, ten domestic companies are in the application stage for Semaglutide, indicating a collective race rather than a single breakthrough [5]. - The competition will not solely be based on pricing but will also involve consistency, supply stability, channel capabilities, and the speed of advancing indications [5]. Group 2: Approval Timeline - The companies most likely to receive approval first for diabetes indications are Jiuyuan Gene and Lizhu Group, with Jiuyuan being the first to submit its application [6]. - Jiuyuan's application for diabetes indication was accepted on April 2, 2024, while Lizhu's application was accepted on June 13, 2024 [6]. - The market expects the first diabetes indication approvals to be granted by the second half of 2026, while weight management indications may not see significant approvals until after 2027 [8]. Group 3: Pricing Strategies - A price war is anticipated, with the original drug already showing price reductions, indicating a preemptive price defense strategy in the GLP-1 market [9]. - The diabetes indication is expected to enter a more intense price competition phase post-approval, while the weight management indication may not see drastic price drops initially due to brand and consumer factors [9]. - The overall trend suggests that Semaglutide will not maintain its previous high-price, scarce, and strong brand premium status in the Chinese market [9].